Joshua Grady, PhD

Joshua Grady, PhD, has a diverse work experience in proteomics and protein homeostasis research. Joshua is currently working as a Principal Scientist in Proteomics at Matchpoint Therapeutics. Before that, they were a Consultant at NextPoint Therapeutics, Inc.

From 2019 to 2021, Joshua was a Senior Lead Scientist at Rekindle Therapeutics, Inc. Prior to that, they worked at Harvard Medical School, where they held multiple roles. From 2018 to 2019, they were the Proteomics Lead for a program project focused on proteostasis failure in aging and neurogenerative diseases. Joshua also worked as a Postdoctoral Fellow from 2016 to 2019, applying proteomic analyses and bioinformatics to explore protein degradation in erythrocytes and aging models of protein misfolding diseases.

In their earlier career, Joshua worked as a Postdoctoral Fellow at Northwestern University from 2013 to 2016, studying the connection between aging and protein homeostasis in C. elegans using LC-MS/MS technology. Joshua completed their PhD at Harvard Medical School from 2006 to 2013, developing technology and methodologies for the identification and quantification of proteins and their post-translational modifications using LC-MS/MS.

Joshua Grady, PhD has an extensive education history. Joshua started their academic journey at the University of Wisconsin-Madison in 2001, where they studied Biochemistry. After completing their studies there in 2003, they moved on to the University of Minnesota and earned their Bachelor of Science degree in Biochemistry by 2005.

Having developed a strong foundation in the field, Joshua then pursued further education at Harvard Medical School. Joshua enrolled in the school in 2006 and dedicated seven years to their studies. During this time, they focused on Cell Biology and Proteomics, eventually earning their Doctor of Philosophy (PhD) degree in 2013.

Overall, Joshua Grady, PhD has an impressive academic background, specializing in Biochemistry during their undergraduate years before delving deeper into Cell Biology and Proteomics during their doctoral studies at Harvard Medical School.